Skip to content
OpenCapital
Get started

Allogene Therapeutics ALLO Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
——
Arcus Biosciences logo
Arcus BiosciencesRCUS
——

Other financials

Income statement

See full
Revenue-—
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's available for sale securities debt securities current?
Allogene Therapeutics (ALLO) reported available for sale securities debt securities current of $236.58M in Q1 2026.
How has Allogene Therapeutics's available for sale securities debt securities current changed year-over-year?
Allogene Therapeutics's available for sale securities debt securities current decreased by 0.4% year-over-year, from $237.59M to $236.58M.
What is the long-term trend for Allogene Therapeutics's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Allogene Therapeutics's available for sale securities debt securities current has grown at a -21.0% compound annual growth rate (CAGR), from $644.56M to $198.52M.